



European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

London, 31 August 2006
Doc. Ref. EMEA/359419/2006

**WORKSHOP ON REGULATORY AND SCIENTIFIC ISSUES RELATED TO THE
INVESTIGATION OF MEDICINAL PRODUCTS INTENDED FOR NEONATAL USE**

**NEONATES WORKSHOP
AGENDA**

Wednesday, 11 October 2006, 09:00-17:00, room 3A
EMA, 7 Westferry Circus, Canary Wharf, London E14 4 HB, UK

Chairperson: Prof. John van den Anker

Welcome and Introduction (John van den Anker)	9.00-9.30
Impact of organ immaturity on the investigation of medicinal products in the neonate (with a view on future guidelines) (John van den Anker)	9.30-10.15
Drug formulations for neonates: lessons learnt, present status and needs (Joerg Breitzkreutz)	10.15-11.00
<i>Coffee Break</i>	11.00-11.30
Specific aspects of pharmacokinetics and pharmacodynamics in neonates (enzyme and receptor maturation / early development of drug metabolism) (Greg Kearns)	11.30-12.15

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel: (44-20) 74 18 84 00, Fax: (44-20) 74 18 86 13
E-mail: mail@emea.europa.eu <http://www.emea.europa.eu>

©EMA 2006 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMA is acknowledged

Invasiveness and non-invasive methods with specific regard to prevention and management of pain in neonates (Vineta Fellman)	12.15-13.00
--	-------------

<i>Lunch Break</i>	<i>13.00-14.00</i>
---------------------------	---------------------------

Ethical aspects, recruitment and informed consent (Pieter Sauer)	14.00-14.45
--	-------------

Methodology, study design and statistical approaches (Gerard Pons)	14.45-15.30
--	-------------

<i>Coffee Break</i>	<i>15.30-16.00</i>
----------------------------	---------------------------

Pharmacovigilance and safety aspects (Dirk Mentzer)	16.00-16.45
---	-------------

Closing remarks (John van den Anker)	16.45-17.00
--	-------------